Yeah the value of the voucher is a vindication of the drug, and the ability of management to engage with the FDA. No one should be disappointed the voucher wasn't granted, because it doesn't work that way. Vouchers are granted upon approval of drug, at which point you can sell them for around 200 usd which is around 300 m AUD. Risk adjusted to today, that's worth around 100m AUD.
Ann: US FDA Grants RPDD to ATL1102 for the treatment of DMD, page-30
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
